Seres Therapeutics, Inc. (MCRB) Stock Forecast
MCRB analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $17.00 average of analyst targets
- Upside to target
- +591.1% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-1.34
- 52-week range
- $2.42 – $28.63
MCRB analyst ratings
2 analystsNumber of analysts at each rating.
MCRB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MCRB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.00 | −$1.34 | −$0.67 | $0.94 | −206.9% | 2 |
| Current fiscal year (2026) | −$3.52 | −$4.36 | −$2.67 | $0.64 | −649.2% | 2 |
| Next fiscal year (2027) | −$4.95 | −$7.02 | −$2.87 | −$3.52 | −40.7% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MCRB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.3M | $200,000 | $12.5M | +1,709.1% | 2 |
| Current fiscal year (2026) | $13.8M | $1.5M | $26.1M | +1,648.7% | 2 |
| Next fiscal year (2027) | $273,500 | $0 | $547,000 | −98.0% | 2 |
MCRB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MCRB revenue: reported and forecast
MCRB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.37 | −$2.37 | −$1.64 | −$1.64 | −$1.00 | −57.6% | 0 up · 1 down |
| Current fiscal year (2026) | −$9.19 | −$9.19 | −$7.51 | −$7.51 | −$3.52 | −61.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$10.28 | −$10.28 | −$6.58 | −$6.58 | −$4.95 | −51.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MCRB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MCRB beat in 8 of 12.
What analysts expect from MCRB
2 analysts cover Seres Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $17.00, 591.1% above the latest close of $2.46. Analysts expect earnings of −$3.52 per share for 2026, −649.2% from a year earlier. For 2027 the average estimate is −$4.95 per share on revenue of $0.3 million. Seres Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: MCRB income statement, MCRB key metrics, MCRB chart. See the MCRB stock overview for the latest quote and news.
MCRB forecast FAQ
What is Seres Therapeutics's price target?
The average analyst price target for Seres Therapeutics is $17.00, 591.1% above the latest close of $2.46.
Is Seres Therapeutics a buy, hold or sell?
Of 2 analysts covering Seres Therapeutics, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Seres Therapeutics's EPS forecast?
Analysts forecast −$3.52 per share for 2026 (range −$4.36 to −$2.67); for 2027 the estimate is −$4.95.
What is Seres Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $13.8 million, growth of 1,648.7%; for 2027 it is $0.3 million.
When does Seres Therapeutics report earnings?
Seres Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $-1.34.
Does Seres Therapeutics usually beat earnings estimates?
Seres Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.